SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix (OCUL) is trending amid escalating rumors of an enhanced acquisition offer from Sanofi, which previously rejected a $16/share bid, coupled with high anticipation for imminent Phase 3 data for AXPAXLI in wet AMD. The recent hire of Eylea's former architect as CCO further fuels community discussion about a potential premium buyout or successful independent launch.

TOSHI

TOSHI is drawing significant community attention, with many anticipating an imminent breakout and substantial price appreciation driven by bullish technical indicators and its prominent status as the "face of Base" ecosystem. Investors are actively discussing accumulation and higher targets as the coin trends across platforms.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is a battleground stock trending amid its ongoing turnaround plan, which includes selling Del Taco to address substantial debt, a move that draws both optimism for simplification and concern over financial losses. The high short interest is fueled by deep-seated debt worries, while a vocal segment anticipates a significant rebound driven by activist investor involvement and growth in core brand operations.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending as strong institutional demand, evidenced by a recently upsized $100M offering, de-risks its lead CAR-T therapy, NXC-201, for AL Amyloidosis. Investors are actively discussing the therapy's impressive clinical datahighlighting zero neurotoxicity and high response ratespositioning IMMX as a potential first-to-market solution and a compelling buyout target within the consolidating CAR-T and autoimmune therapy sectors.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is trending as the community eagerly discusses major deflationary events, including substantial token burns from unclaimed airdrops and buybacks, alongside new product updates like video generation and enhanced API support. Its low circulating supply and utility in private, uncensored AI are key talking points, fueling optimism for significant upside.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is a hot topic following its strong earnings beat, driven by surging demand for its power generation equipment, positioning the industrial giant as a key player in the AI data center build-out. This AI infrastructure narrative has propelled the stock to new highs, sparking widespread debate among investors over its soaring valuation and the sustainability of its remarkable momentum.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP CRYPTO) is a hot topic as its community debates its future amidst recent partnerships, V4 development, and the launch of the Legend app, which proponents believe could drive a significant rebound in the DeFi lending protocol. While bulls highlight limited token supply and new utility in the RWA space, skeptics point to historical underperformance and ongoing governance challenges as major headwinds.

Genius Sports Ltd. engages in the provision of scalable, technology-led products and services to the sports, sports betting, and sports media industries. It also involves in Sports League, which offers technology infrastructure for the collection, integration, and distribution of live data; Sportsbooks, which includes collection of live sports data, odds making, risk management and player marketing; and Sports Media, which provides a range of online marketing and fan engagement tools. The company was founded by Mark Adrian Locke in 2000 and is headquartered in London, United Kingdom.

Genius Sports Limited

Genius Sports is trending following a sharp stock price drop catalyzed by its significant acquisition of Legend, a deal questioned by many in the community for its perceived high cost, added debt, and potential dilution for what some see as a legacy media asset, though management maintains it's a strategic long-term growth play.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is trending due to a recent Coinbase listing for New York residents and widespread community speculation about an impending significant rally, reminiscent of past gains. The cryptocurrency's AI-integrated cross-chain exchange and fully diluted fixed supply are key talking points, with many believing it is currently undervalued.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is actively discussed after a strong Q3 earnings beat and the authorization of a $1 billion share buyback, leading to analyst upgrades and community optimism about its AI agent security potential. Despite this, some investors remain perplexed by the stock's recent price action, citing a lack of explicit long-term guidance as a point of contention amidst broader software sector trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Disc Medicine is Now Oversold (IRON)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Disc Medicine (NASDAQ:IRON) Trading Down 40% - What's Next?

Disc Medicine (NASDAQ:IRON) Stock Price Down 40% - Should You Sell...

<ul class="summary-bullets"><li>The agency said that the company must provide evidence of clinical benefit from “adequate and well-controlled trial(s)” for approval.</li><li>Disc Medicine’s bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program.&nbsp;</li><li>Disc said it would resubmit its application following the completion of its APOLLO trial and expects a fresh decision from the agency by mid-2027.</li></ul>Shares of Disc Medicine (IRON) slumped 21% on Friday after the U.S. Food and Drug Administration refused to approve the company’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria.Disc Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">FDA’s Rationale</h2>The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit. The agency said that the company must now provide evidence of clinical benefit from “adequate and well-controlled trial(s)” for approval.The agency also expressed willingness to meet with the company to discuss options including the completion of an ongoing late-stage trial called Apollo and using it to seek a traditional approval.Disc Medicine was seeking approval of the pill in Erythropoietic Protoporphyria, a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-receives-complete-response-letter-fda-bitopertin">confirmed</a> the receipt of the letter and said that it expects to seek a meeting with the agency.“The CRL will delay the potential approval of bitopertin, but we have confidence in the ongoing APOLLO trial…,” CEO John Quisel said. The company also added that the issues raised by the FDA in the letter are “readily addressable” with data from its APOLLO trial expected in the fourth quarter (Q4).The company said it would resubmit its application following the completion of the APOLLO trial and expects a fresh decision from the agency by mid-2027.Last month, Reuters reported that the FDA has delayed the review of bitopertin after its scientists flagged safety and efficacy concerns. The decision was previously slated for January-end but pushed back two weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user now expects the FDA to decide on an approval for the pills only by late 2027. “Debating whether to start a small position now or wait for further downside,” they wrote.<stembedurl>https://www.stocktwits.com/jamonda/message/644968897</stembedurl><a href="https://stocktwits.com/symbol/IRON">IRON stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-cease-one-time-sale-of-fsd-starting-sunday/cZRdcaLR4t0">Tesla To Cease One-Time Sale Of FSD In Favor Of Subscription Model</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns

The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin. 

Equity

The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin. 


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc...

Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) has been assigned an average rating of "Moderate Buy" from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports...

Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON

Atle Fund Management AB increased its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 85.3% during the 3rd quarter, according to the company in its most recent Form 13F...

Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade

The consensus price target hints at a 48.6% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

HC Wainwright Weighs in on Disc Medicine FY2030 Earnings

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Investment analysts at HC Wainwright issued their FY2030 earnings per share estimates for Disc Medicine in a research note issued on Monday, January...

Disc Medicine (NASDAQ:IRON) Insider Sells $69,740.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 1,000 shares of Disc Medicine stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Stocktwits

Stocktwits Polls

The FDA declined approval for the rare disorder drug Bitopertin due to efficacy concerns, issuing a Complete Response Letter (CRL) that triggered immediate market reaction.

The stock experienced a sharp downturn and trading halt following the FDA news, with many monitoring for a "gap fill" and speculating on future price movements around values like $56.50.

Concerns about market manipulation and illegal insider trading are growing among traders who suspect big money moved ahead of public disclosure of the FDA's critical decision.

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IRON News

IRONDisc Medicine Inc